COA Certified · Every Batch TestedSame-Day Shipping on Orders by 2PM ESTLot-Matched COA · Batch TraceabilityFree Shipping on Orders Over $300≥99% Purity — HPLC + Mass SpecEndotoxin Tested · Sterility VerifiedCOA Certified · Every Batch TestedSame-Day Shipping on Orders by 2PM ESTLot-Matched COA · Batch TraceabilityFree Shipping on Orders Over $300≥99% Purity — HPLC + Mass SpecEndotoxin Tested · Sterility Verified
For Laboratory & Research Use Only — Not for Human or Veterinary Use
All ProductsGLP-1 PeptidesResearch PeptidesPeptide BlendsLiquid SpraysDissolving StripsBioregulatorsResearch BundlesLab SuppliesMerch Search

LY3298176 — Research Summary

Research Use Only · Not for Human or Veterinary Use

Dual GIP/GLP-1 receptor agonist studied for glucose regulation and incretin-pathway res

LY3298176

An evidence summary of published preclinical research on LY3298176. This page is educational and summarizes findings reported in third-party scientific literature. No claims are made regarding safety or efficacy in humans.

Molecular Data

FORMULA C225H348N48O68
MOLECULAR WEIGHT 4,813.45 g/mol
SEQUENCE 39-amino acid linear peptide

Compound Overview

LY3298176 is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It represents a new class of investigational compounds that simultaneously activate both incretin receptors. In clinical research, LY3298176 has demonstrated unprecedented efficacy in glycemic control and weight management studies, making it one of the most significant developments in incretin-pathway research.

Reported Mechanism (Preclinical)

LY3298176 activates both GIP and GLP-1 receptors, producing complementary incretin-pathway effects. GLP-1 receptor activation stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. GIP receptor activation enhances insulin sensitivity, may influence fat metabolism, and appears to potentiate the GLP-1 effects. The dual mechanism produces synergistic incretin-pathway improvements that exceed either pathway alone.

Mechanisms described above are reported in preclinical (animal and in vitro) literature and have not been established for human use.

Key Research Highlights

  • SURPASS clinical trial program demonstrated superior HbA1c reduction vs comparators
  • SURMOUNT trials showed significant body weight reduction in obesity research (up to 22.5%)
  • Demonstrated improvements in cardiovascular risk markers including blood pressure and lipids
  • Showed favorable effects on liver fat content in NAFLD research models
  • Unique dual-agonist mechanism provides insights into incretin biology research

Published References

  1. LY3298176 versus NN9535 once weekly in patients with type 2 diabetes
    N Engl J Med, 2021
  2. LY3298176 once weekly for the treatment of obesity
    N Engl J Med, 2022
  3. Dual GIP and GLP-1 receptor agonism: a new paradigm
    Lancet, 2022

Available for Research

Lab-tested, third-party COA published, U.S. ships same day.

View Product · LY3298176 View COA Library
Compliance Notice: American Peptides products are sold strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature, summarizes findings from preclinical literature, and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution's safety protocols and applicable laws.